Trials / Withdrawn
WithdrawnNCT03760614
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
A Phase Ib Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entinostat | Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. |
| DRUG | FOLFOX regimen | FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2022-07-01
- Completion
- 2022-11-01
- First posted
- 2018-11-30
- Last updated
- 2021-01-15
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03760614. Inclusion in this directory is not an endorsement.